Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

307/433 Matches for
“ALT”

“ALT” Clear all
  1. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

    Ratziu V et al. · J Hepatol · 2011 Match 100

    …The primary study end point was reduction in ALT levels from baseline…

    FibroTest Metabolic

  2. Intermethod calibration of alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) results: application to Fibrotest and Actitest scores.

    Férard G et al. · Clin Chem Lab Med · 2006 Match 100

    …This approach requires standardization of alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT…

    ActiTest FibroTest HBV HCV

  3. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.

    Peta V et al. · PLoS One · 2017 Match 100

    …recovery outcome defined as an ALT <2x the upper limit of normal…

    ActiTest FibroTest Other

  4. Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C.

    Chen SH et al. · BMC Gastroenterol · 2012 Match 100

    …Factors included serum alanine aminotransferase (ALT)/upper limit of normal (ULN) categories…

    FibroTest HCV

  5. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure.

    Poynard T et al. · Gastroenterol Clin Biol · 2010 Match 100

    …in comparison with alanine aminotransferase (ALT) the standard of care. ### Methods Methods…

    ActiTest HCV

  6. Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan.

    Dai CY et al. · J Hepatol · 2010 Match 100

    …The independent factors significantly associated with low platelet count were abnormal ALT

    FibroTest HBV HCV

  7. Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients.

    Miailhes P et al. · J Viral Hepat · 2011 Match 100

    …Patients with elevated ALT tended to have higher LSM than those with…

    FibroTest HBV HIV

  8. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.

    Thabut D et al. · J Hepatol · 2006 Match 99

    ### Background/Aims The aim was to identify a panel of biomarkers (AshTest…

    AshTest Alcohol

  9. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.

    Myers RP et al. · J Hepatol · 2003 Match 99

    …AST, ALT, and Actitest accurately predicted activity ((areas under receiver operating characteristic…

    ActiTest FibroTest HBV

  10. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.

    Poynard T et al. · J Hepatol · 2012 Match 99

    …three techniques, and alanine aminotransferase (ALT) taken as a control test, were…

    FibroTest HCV

  11. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication

    Ngo Y et al. · PLoS One · 2008 Match 99

    ### Background The combination of transaminases (ALT), biopsy, HBeAg and viral load have…

    ActiTest FibroTest HCV

  12. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

    Terrault NA et al. · Hepatology · 2018 Match 99

    ActiTest FibroTest HBV

  13. The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.

    Imbert-Bismut F et al. · Eur J Gastroenterol Hepatol · 2009 Match 99

    …Aspartate aminotransferase/alanine aminotransferase (AST/ALT) was higher in ALD patients with…

    FibroTest SteatoTest Alcohol

  14. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Comp Hepatol · 2005 Match 98

    ### Background Biopsy is the usual gold standard for liver steatosis assessment. The…

    SteatoTest Alcohol HBV HCV +1

  15. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors.

    Imbert-Bismut F et al. · Clin Chem Lab Med · 2004 Match 98

    Combinations of tests comprising alpha2-macroglobulin, haptoglobin, apolipoprotein Al, gamma-glutamyltransferase, total…

    ActiTest FibroTest HCV

  16. FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases.

    Castera L et al. · Hepatology · 2006 Match 98

    FibroTest HCV

  17. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease.

    Halfon P et al. · Comp Hepatol · 2002 Match 98

    BACKGROUND: Biochemical markers for liver fibrosis (FibroTest) and necroinflammatory features (ActiTest) are…

    ActiTest FibroTest Alcohol HCV

  18. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

    Match 98

    FibroTest HBV

  19. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.

    Harris R et al. · Lancet Gastroenterol Hepatol · 2017 Match 98

    As of 2016, there is no evidence-based pathway to stratify the…

    FibroTest Other

  20. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.

    Sberna AL et al. · Diabet Med · 2018 Match 97

    ### Aims To evaluate the application of the recently proposed recommendations by the…

    FibroTest NashTest Metabolic

  21. Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.

    Copaci I et al. · Rom J Intern Med · 2015 Match 97

    …Factors associated with regression of steatosis were weight, BMI, ALT, waist circumference…

    SteatoTest Metabolic

  22. FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B.

    Zeremski M et al. · BMC Gastroenterol · 2014 Match 97

    ### Background Noninvasive markers of liver fibrosis have not been extensively studied in…

    ActiTest FibroTest HBV

  23. Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

    Peta V et al. · World J Hepatol · 2025 Match 97

    …0.73-0.90) for ALT (_P_ = 0.06). The OM values…

    ActiTest FibroTest AIH

  24. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases.

    Colletta C et al. · Hepatology · 2005 Match 97

    The course of hepatitis C virus (HCV) infection carriers with normal/near…

    FibroTest HCV

  25. Liver stiffness measurement and biochemical markers in Senegalese chronic hepatitis B patients with normal ALT and high viral load.

    Mbaye PS et al. · PLoS One · 2011 Match 97

    …mL and normal alanine aminotransferase (ALT) values. ### Methods LSM and liver fibrosis…

    FibroTest HBV

  26. Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.

    Guiu B et al. · Eur Radiol · 2012 Match 96

    ### Objectives The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI…

    SteatoTest Metabolic

  27. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.

    Rudler M et al. · PLoS One · 2015 Match 96

    …AST/ALT 0.833 (0.023); P = 0.01], as well as…

    AshTest Alcohol

  28. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases.

    Sebastiani G et al. · J Viral Hepat · 2008 Match 96

    …ratio, Forns' index, AST-to-ALT ratio (AAR), Fibrotest and the recently…

    FibroTest HCV

  29. Progression of liver fibrosis among injection drug users with chronic hepatitis C.

    Wilson LE et al. · Hepatology · 2006 Match 96

    …In this setting with low fibrosis prevalence, FibroSURE, ALT, and APRI tests…

    FibroTest

  30. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.

    Vilar-Gomez E et al. · J Hepatol · 2018 Match 96

    The correct identification of patients at increased risk of non-alcoholic steatohepatitis…

    FibroTest Metabolic

  31. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases.

    Coco B et al. · J Viral Hepat · 2007 Match 96

    …Other than fibrosis, other factors independently associated with liver stiffness were ALT

    FibroTest Alcohol HBV HCV +1

  32. Discordance between liver biopsy and FibroTest in assessing liver fibrosis in chronic hepatitis B.

    Park MS et al. · PLoS One · 2013 Match 95

    …After adjusting fibrosis stages, neither necroinflammatory activity on histology nor serum ALT

    FibroTest HBV

  33. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

    European Association For The Study Of The Liver · J Hepatol · 2012 Match 95

    ActiTest FibroTest HBV

  34. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.

    Steininger K et al. · J Viral Hepat · 2017 Match 95

    …HCV RNA levels, and higher ALT levels upon initial acute HCV diagnosis…

    FibroTest HCV HIV

  35. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication

    Poynard T et al. · BMC Gastroenterol · 2006 Match 95

    …haptoglobin, gamma-glutamyl-transpeptidase, transaminases ALT, AST, and total bilirubin. AUROCs of…

    NashTest Metabolic

  36. Diagnostic value of FibroTest with normal serum aminotransferases.

    Poynard T et al. · Hepatology · 2006 Match 95

    FibroTest HCV

  37. FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence.

    Poynard T et al. · J Viral Hepat · 2008 Match 95

    FibroTest HCV

  38. Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.

    Vermehren J et al. · BMC Gastroenterol · 2012 Match 94

    …Chronic ALT, AST and γ-GT elevation was present in 29%, 20…

    FibroTest HCV HIV

  39. FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2011 Match 94

    ### Background Two widely used biomarkers of fibrosis, FibroTest and liver stiffness measurement…

    FibroTest HCV

  40. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.

    Netanel C et al. · Am J Surg · 2021 Match 94

    …Concomitantly, significant improvements in triglycerides, ALT, diabetes markers and adiponectin were observed…

    FibroTest NashTest SteatoTest Metabolic

  41. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.

    Poynard T et al. · PLoS One · 2012 Match 94

    ### Background Liver biopsy is considered as the gold standard for assessing non…

    ActiTest FibroTest NashTest SteatoTest +1

  42. Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C.

    Usluer G et al. · Eur J Clin Microbiol Infect Dis · 2012 Match 94

    …The platelet count, AST/ALT ratio (AAR), cirrhosis discriminate score (CDS), FIB4…

    FibroTest HCV

  43. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores.

    Castéra L et al. · J Hepatol · 2009 Match 94

    …available non-invasive methods (AST/ALT ratio (AAR), APRI, prothrombin index (PI…

    FibroTest HCV

  44. Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".

    Perazzo H et al. · Clin Res Hepatol Gastroenterol · 2014 Match 93

    ### Background The aspartate aminotransferase platelet ratio index (APRI) is a validated, non…

    FibroTest Alcohol HBV HCV +1

  45. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C.

    Sebastiani G et al. · J Hepatol · 2006 Match 93

    …hepatitis C carriers with normal ALT. (3) Identification of cirrhosis (95% accuracy…

    FibroTest HCV

  46. Hepatitis B: are non-invasive markers of liver fibrosis reliable?

    Castera L · Liver Int · 2014 Match 93

    …positive results in case of ALT flares. Although these non-invasive methods…

    FibroTest HBV HCV

  47. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.

    Laharie D et al. · J Hepatol · 2010 Match 93

    ### Background & Aims Although methotrexate (MTX) is used in the effective treatment of…

    FibroTest Other

  48. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

    Thabut D et al. · Am J Gastroenterol · 2006 Match 93

    …Patients>80 yr (43%) with cirrhosis had nonelevated alanine amino transferase (ALT

    FibroTest HCV

  49. Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.

    de Lédinghen V et al. · Dig Liver Dis · 2012 Match 93

    ### Background Patients with diabetes are at risk for nonalcoholic fatty liver disease…

    FibroTest Metabolic

  50. Biomarkers for liver disease in urea cycle disorders.

    Nagamani SCS et al. · Mol Genet Metab · 2021 Match 93

    ### Background Urea cycle disorders (UCDs) are among the most common inborn errors…

    ActiTest FibroTest Other

  51. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.

    Lassailly G et al. · Eur J Gastroenterol Hepatol · 2011 Match 92

    ### Background Liver biopsy is considered as the gold standard for assessing nonalcoholic…

    FibroTest NashTest SteatoTest Metabolic

  52. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication

    Ratziu V et al. · BMC Gastroenterol · 2006 Match 92

    ### Background Liver biopsy is considered as the gold standard for assessing non…

    FibroTest Metabolic

  53. Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).

    Munteanu M et al. · Comp Hepatol · 2004 Match 92

    BACKGROUND: Biochemical marker combinations, including alpha2-macroglobulin, haptoglobin, apolipoprotein A1, gamma-glutamyl…

    ActiTest FibroTest Alcohol HBV +3

  54. Comparison of noninvasive models of fibrosis in chronic hepatitis B.

    Raftopoulos SC et al. · Hepatol Int · 2012 Match 92

    …Among 73 patients with an ALT <60 IU/L, noninvasive models were…

    FibroTest HBV

  55. Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis.

    Alric L et al. · Transpl Int · 2009 Match 92

    To assess the accuracy of the noninvasive tools, fibrotest (FT) and liver…

    FibroTest HBV HCV

  56. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2011 Match 92

    …APRI, Forns'index, Lok index, AST-to-ALT ratio, Fib-4, platelets…

    FibroTest HBV HCV HIV +1

  57. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.

    Castéra L et al. · Aliment Pharmacol Ther · 2011 Match 91

    ### Background Non invasive methods for fibrosis evaluation remain to be validated longitudinally…

    FibroTest HBV

  58. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.

    Grattagliano I et al. · Ann Hepatol · 2013 Match 91

    …Steatotest score was significantly associated with BMI, waist circumference, ALT, triglycerides, and…

    ActiTest FibroTest NashTest SteatoTest +1

  59. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.

    Vallet-Pichard A et al. · Hepatology · 2007 Match 91

    …combines standard biochemical values (platelets, ALT, AST) and age, in a series…

    FibroTest HCV

  60. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

    Poynard T et al. · J Hepatol · 2012 Match 91

    ### Background & Aims Time-dependent statistics have been used to assess liver fibrosis…

    FibroTest Alcohol HBV HCV +1

  61. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.

    Parikh P et al. · Ann Transl Med · 2017 Match 91

    Chronic hepatitis B virus (HBV) infection is a major cause of liver…

    FibroTest HBV

  62. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.

    Chou R et al. · Ann Intern Med · 2013 Match 91

    ### Background Many blood tests have been proposed as alternatives to liver biopsy…

    FibroTest HCV

  63. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.

    Bottero J et al. · J Hepatol · 2009 Match 90

    ### Background/Aims The aim of this study was to compare the performance…

    FibroTest HBV HIV

  64. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.

    Poynard T et al. · Curr Hepat Rep · 2011 Match 90

    A serum biomarker (FibroTest; Biopredictive, Paris, France; FibroSure; LabCorp, Burlington, USA) and…

    FibroTest HBV

  65. The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B.

    Mallet V et al. · Aliment Pharmacol Ther · 2009 Match 90

    ### Background The Fib-4 index is a simple and inexpensive biomarker to…

    FibroTest HBV

  66. Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus.

    de Lédinghen V et al. · Aliment Pharmacol Ther · 2013 Match 90

    ### Background Liver stiffness and non-invasive tests predict overall survival in chronic…

    FibroTest HBV

  67. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Key publication

    Imbert-Bismut F et al. · Lancet · 2001 Match 90

    ### Background Liver biopsy is thought mandatory for management of patients with hepatitis…

    FibroTest HCV

  68. A reference material for traceability of aspartate aminotransferase (AST) results.

    Férard G et al. · Clin Chem Lab Med · 2005 Match 90

    Standardization of aspartate aminotransferase (AST) determination is highly desirable for inter-laboratory…

    HBV HCV

  69. PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.

    Petit JM et al. · Liver Int · 2011 Match 89

    ### Context Recently, it has been shown that an allele in the adiponutrin…

    FibroTest Metabolic

  70. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Match 89

    FibroTest Alcohol HBV HCV +3

  71. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive.

    Boursier J et al. · Hepatology · 2012 Match 89

    ### Unlabelled The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm…

    FibroTest HCV

  72. Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.

    Flores-Calderón J et al. · Ann Hepatol · 2012 Match 89

    ### Introduction Identifying liver fibrosis is important to evaluate the severity of liver…

    FibroTest

  73. Usefulness of acoustic radiation force impulse and fibrotest in liver fibrosis assessment after liver transplant.

    Bignulin S et al. · Ann Hepatol · 2016 Match 89

    ### Unlabelled Background and rationale. Acoustic radiation force impulse (ARFI) is a non…

    FibroTest HCV

  74. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).

    Poynard T et al. · J Hepatol · 2014 Match 89

    …viral load, HBeAg status and ALT, FT, and TE were predictive of…

    ActiTest FibroTest HBV

  75. The use of enzyme results for liver fibrosis evaluation neccessitates standardization.

    Myara A et al. · Hepatology · 2008 Match 88

    FibroTest HBV HCV HIV

  76. Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.

    Meritsi A et al. · Clin Diabetes · 2022 Match 88

    ActiTest FibroTest NashTest-2 Metabolic

  77. Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation.

    Elalfy MS et al. · Ann Hepatol · 2013 Match 88

    …Patients with HCV viremia showed significantly higher ALT, γ-glutamyl transpeptidase (GGT…

    ActiTest FibroTest HCV

  78. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

    Lemoine M et al. · J Acquir Immune Defic Syndr · 2019 Match 88

    ### Background HIV-monoinfected individuals are at high risk of nonalcoholic fatty liver…

    FibroTest NashTest SteatoTest HIV

  79. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.

    Ahmad W et al. · Virol J · 2011 Match 88

    ### Background Chronic HCV is one of the major causes of morbidity and…

    FibroTest HCV

  80. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.

    Poynard T et al. · Clin Chem · 2004 Match 88

    ### Background The FibroTest and ActiTest are noninvasive biochemical markers of liver injury…

    ActiTest FibroTest HCV

  81. Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.

    Poinsot P et al. · J Clin Lipidol · 2017 Match 87

    ### Background The childhood/adult-onset lysosomal acid lipase deficiency (LALD; late-onset…

    FibroTest Metabolic

  82. Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab.

    Geri G et al. · J Viral Hepat · 2012 Match 87

    …The alanine aminotransferase (ALT) level and HCV viral load did not increase…

    FibroTest Alcohol HBV HCV +1

  83. Reproducibility of blood tests of liver fibrosis in clinical practice.

    Calès P et al. · Clin Biochem · 2008 Match 87

    ### Objectives To evaluate the inter-laboratory reproducibility of blood test for liver…

    FibroTest Alcohol HBV HCV +1

  84. Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.

    Zarski JP et al. · Liver Int · 2010 Match 87

    ### Background The efficacy of a maintenance therapy in non-responder patients with…

    ActiTest FibroTest HCV

  85. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication

    Halfon P et al. · Gastroenterol Clin Biol · 2008 Match 87

    FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients…

    FibroTest Alcohol HBV HCV +2

  86. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication

    Poynard T et al. · PLoS One · 2020 Match 87

    ### Background Since 1920, a decrease in serum cholesterol has been identified as…

    FibroTest COVID

  87. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.

    Poynard T et al. · Hepatology · 2003 Match 86

    Liver fibrosis and activity indexes were validated in patients infected by hepatitis…

    ActiTest FibroTest HCV

  88. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.

    Poynard T et al. · Ann Intern Med · 2013 Match 86

    FibroTest HCV

  89. Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C.

    Fontanges T et al. · Gastroenterol Clin Biol · 2008 Match 86

    …0.0001) and alanine aminotransferase (ALT) (p<0.0001) was observed in…

    ActiTest FibroTest HCV

  90. Noninvasive evaluation of NAFLD.

    Castera L et al. · Nat Rev Gastroenterol Hepatol · 2013 Match 86

    A common clinical concern in patients with NAFLD is whether they have…

    ActiTest FibroTest NashTest SteatoTest +1

  91. Non-invasive markers for hepatic fibrosis.

    Baranova A et al. · BMC Gastroenterol · 2011 Match 86

    With great advancements in the therapeutic modalities used for the treatment of…

    FibroTest Alcohol HBV HCV +3

  92. Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study.

    Köksal İ et al. · Turk J Gastroenterol · 2018 Match 86

    ### Background/Aims The hepatitis C virus (HCV) infection is important cause of…

    FibroTest HCV

  93. Retracted: Executive functions in chronic hepatitis C virus infected elderly patients.

    · Geriatr Gerontol Int · 2015 Match 86

    FibroTest HCV

  94. Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings.

    Pan CQ et al. · PLoS One · 2014 Match 85

    ### Background And Aims Chronic hepatitis B (CHB) disproportionately affects the Asian-American…

    FibroTest HBV

  95. Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters?

    Gentile I et al. · Infez Med · 2014 Match 85

    It is estimated that hepatitis C virus (HCV) infects chronically about 160…

    FibroTest HCV

  96. Predicting significant fibrosis in hepatitis C patients in Luxembourg using serological markers.

    Mossong J et al. · Bull Soc Sci Med Grand Duche Luxemb · 2011 Match 85

    ### Objective The aim of our study was to assess the diagnostic performance…

    FibroTest HCV

  97. Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.

    Salles N et al. · Gastroenterol Clin Biol · 2009 Match 85

    ### Aim The objective of this study was to evaluate liver fibrosis using…

    FibroTest

  98. The non-invasive assessment of hepatic fibrosis.

    Gheorghe G et al. · J Formos Med Assoc · 2021 Match 85

    Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis…

    ActiTest FibroTest Alcohol HBV +2

  99. Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.

    Naveau S et al. · Eur J Gastroenterol Hepatol · 2014 Match 85

    ### Background And Aims The PGAA index was one of the first composite…

    FibroTest Alcohol

  100. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.

    Adams LA et al. · J Gastroenterol Hepatol · 2011 Match 84

    ### Background And Aim Significant hepatic fibrosis is prognostic of liver morbidity and…

    FibroTest Metabolic

  101. Changes of non-invasive markers and FibroScan values during HCV treatment.

    Vergniol J et al. · J Viral Hepat · 2009 Match 84

    The recent advent of non-invasive methods for assessment of fibrosis allows…

    FibroTest HCV

  102. Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers.

    Friedrich-Rust M et al. · J Thorac Cardiovasc Surg · 2008 Match 84

    ### Objective Studies have shown that patients with failing Fontan circulation may develop…

    ActiTest FibroTest Other

  103. [Biomarkers for liver fibrosis: advances, advantages and disadvantages].

    Cequera A et al. · Rev Gastroenterol Mex · 2014 Match 84

    Liver cirrhosis in Mexico is one of the most important causes of…

    FibroTest HCV

  104. Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.

    Boyd A et al. · J Int AIDS Soc · 2017 Match 84

    ### Introduction Long-term tenofovir disoproxil fumarate (TDF) use has been associated with…

    FibroTest HBV HIV

  105. EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

    European Association for the Study of the Liver · J Hepatol · 2011 Match 84

    ActiTest FibroTest HCV

  106. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.

    Rinella ME et al. · J Hepatol · 2022 Match 83

    …from baseline in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase…

    FibroTest Metabolic

  107. Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.

    Halfon P et al. · Antivir Ther · 2009 Match 83

    ### Background Non-invasive liver fibrosis scores have been proposed as alternatives to…

    FibroTest HCV HIV

  108. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.

    Lombardi R et al. · World J Gastroenterol · 2015 Match 83

    Alcoholic liver disease (ALD) consists of a broad spectrum of disorders, ranging…

    FibroTest Alcohol

  109. Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.

    Poynard T et al. · J Hepatol · 2013 Match 83

    ### Background & Aims Therapeutic options for patients failing hepatitis C retreatment are limited…

    ActiTest FibroTest HBV

  110. The role of the non-invasive serum marker FibroTest-ActiTest in the prediction of histological stage of fibrosis and activity in children with naïve chronic hepatitis B infection.

    Sökücü S et al. · Scand J Infect Dis · 2010 Match 83

    The aim of this study was to investigate whether the non-invasive…

    ActiTest FibroTest HBV

  111. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.

    Ratziu V et al. · Aliment Pharmacol Ther · 2007 Match 83

    ### Background Mortality related to complications of cirrhosis is increasing in patients with…

    FibroTest NashTest SteatoTest Metabolic

  112. Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2012 Match 82

    ### Background FibroTest(®) (FT), and liver stiffness measurement (LSM) are the most validated…

    Elasto-FibroTest FibroTest HCV

  113. Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.

    Denimal D et al. · Cardiovasc Diabetol · 2024 Match 82

    ### Background Studies have demonstrated that coronary artery calcification on one hand and…

    ActiTest FibroTest NashTest SteatoTest +1

  114. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.

    Matta B et al. · Curr HIV/AIDS Rep · 2016 Match 82

    Patients with HIV have a proclivity to develop liver fibrosis, especially when…

    FibroTest HBV HCV HIV

  115. [Alpha 2 macroglobulin immunoturbidimetric assays (DakoCytomation reagents) on Roche Diagnostic analysers (Modular P, Cobas Integra). Application to FibroTest-Actic-Test].

    Piton A et al. · Ann Biol Clin (Paris) · 2005 Match 82

    …A1, total bilirubin, GGT and ALT) to Roche Diagnostics equipment by comparing…

    ActiTest FibroTest

  116. Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients.

    Stibbe KJ et al. · Scand J Gastroenterol · 2011 Match 82

    ### Objective Chronic viral hepatitis B and C cause liver fibrosis, leading to…

    FibroTest HBV HCV

  117. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Key publication

    Poynard T et al. · J Viral Hepat · 2009 Match 82

    The aim was to assess the utility of FibroTest-ActiTest (FT-AT…

    ActiTest FibroTest HBV

  118. Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

    Denimal D et al. · Cardiovasc Diabetol · 2025 Match 81

    ### Background Studies have demonstrated that both lower limb arterial calcification and metabolic…

    ActiTest FibroTest NashTest SteatoTest +1

  119. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy.

    Anastasiou J et al. · Eur J Gastroenterol Hepatol · 2010 Match 81

    ### Background The efficiency of transient elastography for the assessment of liver fibrosis…

    ActiTest FibroTest Alcohol HBV +3

  120. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02.

    Cacoub P et al. · J Hepatol · 2008 Match 81

    ### Background/Aims To compare non-invasive biological liver fibrosis scores, as alternatives…

    FibroTest HCV HIV

  121. Concordance of non-invasive serology-based scoring indices and transient elastography for liver fibrosis and cirrhosis in chronic hepatitis C.

    Trnačević E et al. · Med Glas (Zenica) · 2021 Match 81

    Aim To assess concordance of eight frequently used serology-based scoring indices…

    FibroTest HCV

  122. Analytical variability of the Fibrotest proteins.

    Rosenthal-Allieri MA et al. · Clin Biochem · 2005 Match 81

    ### Objectives The analytical variability of the Fibrotest (FT) parameters raises the issue…

    FibroTest HCV

  123. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.

    Minville C et al. · Chest · 2014 Match 81

    ### Background Nocturnal hypoxia, the hallmark of OSA, is a potential contributing factor…

    FibroTest NashTest SteatoTest Metabolic

  124. Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.

    Gressner OA et al. · Clin Chim Acta · 2009 Match 80

    …liver fibrosis. ### Methods (i) Haptoglobin, ALT, gamma GT, alpha-2-macroglobulin, apolipoprotein…

    ActiTest FibroTest HCV

  125. Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients.

    Fidai A et al. · Front Cardiovasc Med · 2017 Match 80

    Fontan-associated liver disease (FALD) is a serious complication related to the…

    FibroTest Other

  126. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C.

    Shlomai A et al. · J Viral Hepat · 2013 Match 80

    Serum bile acids (SBAs) are commonly elevated in cholestatic liver diseases, but…

    FibroTest HCV

  127. Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B.

    Kim BK et al. · PLoS One · 2012 Match 80

    ### Background And Aims Diagnostic values of FibroTest (FT) for hepatic fibrosis have…

    FibroTest HBV

  128. Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience.

    Yakoob R et al. · Ann Gastroenterol · 2015 Match 80

    ### Background The aim of this study was to compare noninvasive biomarkers, FibroTest…

    ActiTest FibroTest HCV

  129. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.

    Zelber-Sagi S et al. · Transl Res · 2015 Match 80

    Retrospective studies suggest that coffee consumption may exert beneficial effects in patients…

    FibroTest SteatoTest Metabolic

  130. Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.

    Rubio A et al. · J Pediatr Gastroenterol Nutr · 2009 Match 79

    ### Objectives : Progressive liver injury is a concern in HIV-infected children exposed…

    FibroTest HIV

  131. Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics.

    Chrostek L et al. · Biomed Res Int · 2019 Match 79

    The aim of this study was to evaluate the diagnostic values of…

    FibroTest Alcohol

  132. Assessment of liver fibrosis: noninvasive means.

    Poynard T et al. · Saudi J Gastroenterol · 2008 Match 79

    Liver biopsy, owing to its limitations and risks, is an imperfect gold…

    FibroTest Alcohol HBV HCV +3

  133. The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).

    Cylwik B et al. · J Clin Med · 2023 Match 79

    The aim of this study was to evaluate the diagnostic usefulness of…

    FibroTest Other

  134. Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B.

    Kim BK et al. · PLoS One · 2012 Match 79

    ### Background And Aims Liver stiffness measurement (LSM) and FibroTest (FT) are frequently…

    FibroTest HBV

  135. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.

    Simental-Mendía LE et al. · Ann Hepatol · 2016 Match 79

    ### Unlabelled Introduction and aim. Given that early identification of non-alcoholic fatty…

    NashTest SteatoTest Metabolic

  136. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis.

    Castera L · J Viral Hepat · 2009 Match 79

    The limitations of liver biopsy (invasive procedure, sampling errors, inter-observer variability…

    FibroTest HBV HCV HIV

  137. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases.

    Adler M et al. · Hepatology · 2008 Match 78

    FibroTest Alcohol HBV HCV +1

  138. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.

    Patel K et al. · J Viral Hepat · 2009 Match 78

    Noninvasive markers that accurately follow changes in fibrosis may provide alternatives to…

    FibroTest HCV

  139. Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography.

    Knop V et al. · Nutrition · 2019 Match 78

    ### Objective Patients with short bowel syndrome (SBS) receiving long-term parenteral nutrition…

    FibroTest SteatoTest Other

  140. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

    European Association for the Study of the Liver (EASL) et al. · Obes Facts · 2016 Match 78

    FibroTest SteatoTest Metabolic

  141. A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers.

    d'Arondel C et al. · J Viral Hepat · 2006 Match 78

    In therapy with standard interferon and ribavirin, five independent risk factors (RF…

    ActiTest FibroTest HCV

  142. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.

    Lynch M et al. · JAMA Dermatol · 2014 Match 78

    ### Importance There is a need for noninvasive tools to monitor hepatotoxicity in…

    FibroTest Other

  143. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study.

    Halfon P et al. · Am J Gastroenterol · 2006 Match 77

    ### Objectives Fibrotest (FT) and Actitest (AT) are biochemical markers of fibrosis and…

    ActiTest FibroTest HCV

  144. Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.

    Giannini EG et al. · J Gastroenterol Hepatol · 2015 Match 77

    ### Background And Aim Thrombocytopenia is frequently observed in patients with chronic hepatitis…

    FibroTest HCV

  145. Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.

    Ciećko-Michalska I et al. · Arch Med Sci Atheroscler Dis · 2018 Match 77

    ### Introduction Nonalcoholic fatty liver disease (NAFLD) is one of the most common…

    ActiTest FibroTest SteatoTest Metabolic

  146. Non-invasive diagnosis of hepatitis B virus-related cirrhosis.

    Lee S et al. · World J Gastroenterol · 2014 Match 77

    Chronic hepatitis B (CHB) infection is a major public health problem associated…

    FibroTest HBV

  147. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

    Munteanu M et al. · Aliment Pharmacol Ther · 2016 Match 77

    ### Background Blood tests of liver injury are less well validated in non…

    ActiTest FibroTest SteatoTest Metabolic

  148. Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt.

    Bonnard P et al. · J Viral Hepat · 2015 Match 77

    In Egypt, as elsewhere, liver biopsy (LB) remains the gold standard to…

    FibroTest HCV

  149. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).

    Poynard T et al. · BMC Gastroenterol · 2010 Match 76

    ### Background FibroTest and elastography have been validated as biomarkers of liver fibrosis…

    FibroTest Alcohol HBV HCV +3

  150. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.

    Zelber-Sagi S et al. · Hepatology · 2008 Match 76

    ### Unlabelled Physical activity (PA) is commonly recommended for nonalchoholic fatty liver disease…

    SteatoTest Metabolic

  151. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication

    Munteanu M et al. · J Gastrointestin Liver Dis · 2008 Match 76

    ActiTest AshTest FibroTest NashTest +6

  152. Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.

    Braha A et al. · J Clin Med · 2024 Match 76

    **Background/Objectives**: Prior research has identified a significant association between heart disease…

    FibroTest Metabolic

  153. [SWE elastography in assessment of liver fibrosis].

    Zaleska-Dorobisz U et al. · Postepy Hig Med Dosw (Online) · 2015 Match 76

    Liver fibrosis is a relatively common consequence of chronic liver diseases, especially…

    FibroTest HBV HCV

  154. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.

    Bril F et al. · Diabetes Care · 2020 Match 76

    …NASH and advanced fibrosis (NASH: ALT, cytokeratin-18, NashTest 2, HAIR, BARD…

    FibroTest NashTest-2 Metabolic

  155. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.

    Thiele M et al. · Gastroenterology · 2018 Match 75

    ### Background & Aims Alcohol is the leading cause of cirrhosis and liver-related…

    FibroTest Alcohol

  156. Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection.

    Hermeziu B et al. · Gastroenterol Clin Biol · 2010 Match 75

    FibroTest-ActiTest (FT-AT) has been validated in adults with chronic hepatitis…

    ActiTest FibroTest HCV

  157. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review

    Moreno C et al. · J Hepatol · 2019 Match 75

    Even though alcohol-related liver disease (ALD) is a major cause of…

    FibroTest Alcohol

  158. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.

    Viglino D et al. · Eur Respir J · 2017 Match 75

    Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…

    FibroTest NashTest SteatoTest Metabolic

  159. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.

    Castéra L et al. · J Hepatol · 2010 Match 75

    ### Background & Aims Non-invasive assessment of liver fibrosis is a challenging area…

    FibroTest HCV

  160. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.

    Poynard T et al. · Aliment Pharmacol Ther · 2023 Match 75

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

  161. Severity of Fontan-Associated Liver Disease Correlates with Fontan Hemodynamics.

    Schleiger A et al. · Pediatr Cardiol · 2020 Match 74

    Fontan-palliated patients are at risk for the development of Fontan-associated…

    FibroTest Other

  162. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.

    Sebastiani G et al. · World J Gastroenterol · 2007 Match 74

    …AST-to-Platelet ratio (APRI), Fornso index, AST-to-ALT Ratio, Goteborg…

    FibroTest HBV

  163. Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis.

    Sène D et al. · Clin Biochem · 2006 Match 74

    ### Objective And Methods We assessed the reliability of non-invasive biological scoring…

    ActiTest FibroTest HCV

  164. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.

    Perazzo H et al. · Aliment Pharmacol Ther · 2014 Match 74

    ### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…

    FibroTest SteatoTest Metabolic

  165. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review

    Bril F et al. · Diabetes Care · 2017 Match 74

    Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…

    FibroTest Metabolic

  166. Real-time tissue elastography versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver disease.

    Friedrich-Rust M et al. · Ultraschall Med · 2009 Match 74

    ### Purpose Transient elastography (FibroScan, [TE]) and serum fibrosis markers such as the…

    FibroTest Alcohol HBV HCV +2

  167. Altered serum N-glycomics in chronic hepatitis B patients.

    Gui HL et al. · Liver Int · 2010 Match 73

    ### Background We previously reported on serum N-glycans as markers for the…

    FibroTest HBV

  168. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.

    de Lédinghen V et al. · Liver Int · 2012 Match 73

    ### Introduction Recently, a study showed that Controlled Attenuation Parameter (CAP), evaluated with…

    SteatoTest Metabolic

  169. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.

    Poynard T et al. · PLoS One · 2008 Match 73

    ### Background Assessing liver fibrosis is traditionally performed by biopsy, an imperfect gold…

    FibroTest Alcohol HBV HCV +3

  170. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Key publication

    Ngo Y et al. · Clin Chem · 2006 Match 73

    ### Background FibroTest, a noninvasive method of measuring biomarkers of liver fibrosis, is…

    FibroTest HCV

  171. Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease.

    Voican CS et al. · Liver Int · 2017 Match 73

    ### Background & Aims The reliability of transient elastography (TE) to assess liver fibrosis…

    FibroTest Alcohol

  172. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.

    Boursier J et al. · Clin Gastroenterol Hepatol · 2023 Match 73

    ### Background & Aims Noninvasive tests (NITs) of liver fibrosis have been suggested to…

    FibroTest Metabolic

  173. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication

    Myers RP et al. · Can J Gastroenterol · 2012 Match 72

    Chronic hepatitis C remains a significant medical and economic burden in Canada…

    FibroTest HCV

  174. Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.

    Chiou YL et al. · J Am Coll Nutr · 2021 Match 72

    ### Objective Nonalcoholic steatohepatitis (NASH) has become a prominent liver disease in contemporary…

    ActiTest FibroTest SteatoTest Metabolic

  175. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2013 Match 72

    FibroTest Metabolic

  176. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness.

    Stasi C et al. · World J Gastroenterol · 2016 Match 72

    The assessment of the fibrotic evolution of chronic hepatitis has always been…

    FibroTest HCV

  177. Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.

    Crisan D et al. · Indian J Med Res · 2017 Match 72

    ### Background & Objectives One of the multiple factors contributing to virological response in…

    ActiTest FibroTest SteatoTest HCV

  178. A novel panel of blood markers to assess the degree of liver fibrosis.

    Calès P et al. · Hepatology · 2005 Match 72

    The objective was to develop new blood tests to characterize different fibrosis…

    FibroTest Alcohol HBV HCV

  179. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Key publication

    Naveau S et al. · Hepatology · 2009 Match 72

    FibroTest has been validated as a biomarker of fibrosis in patients with…

    ActiTest AshTest FibroTest Alcohol

  180. Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C.

    Canbakan M et al. · Nephron Clin Pract · 2011 Match 71

    ### Background Liver biopsy is an imperfect gold standard for assessing the disease…

    FibroTest HCV

  181. Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis.

    Friedrich-Rust M et al. · J Cyst Fibros · 2013 Match 71

    ### Background Patients with cystic fibrosis (CF) have a relevant morbidity and mortality…

    FibroTest Other

  182. Hepatic and renal end-organ damage in the Fontan circulation: A report from the Australian and New Zealand Fontan Registry.

    Wilson TG et al. · Int J Cardiol · 2018 Match 71

    ### Background Hepatic and renal dysfunction have been observed in survivors of the…

    FibroTest Other

  183. Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients.

    Sebagh M et al. · J Hepatol · 2012 Match 71

    ### Background & Aims Most liver transplant centres have discontinued the practice of protocol…

    ActiTest FibroTest Alcohol HBV +4

  184. Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C.

    Sturm N et al. · Liver Int · 2013 Match 71

    ### Background Liver fibrosis, now assessed by liver biopsy or using non-invasive…

    FibroTest HBV HCV

  185. Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.

    Fouad A et al. · Int J Gen Med · 2013 Match 71

    ### Background Steatosis is common in patients with hepatitis C virus (HCV) infection…

    HCV

  186. Validation of Ten Noninvasive Diagnostic Models for Prediction of Liver Fibrosis in Patients with Chronic Hepatitis B.

    Cheng J et al. · PLoS One · 2015 Match 70

    ### Background And Aims Noninvasive models have been developed for fibrosis assessment in…

    FibroTest HBV

  187. FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients.

    Vallet-Pichard A et al. · Hepatology · 2006 Match 70

    FibroTest HCV

  188. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver.

    Laharie D et al. · Eur J Gastroenterol Hepatol · 2010 Match 70

    ### Background The only way to diagnose nodular regenerative hyperplasia (NRH) is liver…

    FibroTest Other

  189. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C.

    Leroy V et al. · J Hepatol · 2007 Match 70

    ### Background/Aims Non-invasive markers of liver fibrosis have recently been developed…

    FibroTest HCV

  190. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.

    Houot M et al. · Aliment Pharmacol Ther · 2016 Match 70

    ### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…

    FibroTest HBV HCV

  191. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication

    AASLD/IDSA HCV Guidance Panel · Hepatology · 2015 Match 70

    ActiTest FibroTest HCV

  192. Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis.

    Fierbinteanu-Braticevici C et al. · World J Gastroenterol · 2009 Match 69

    ### Aim To investigate the diagnostic accuracy of acoustic radiation force impulse (ARFI…

    FibroTest HCV

  193. Biomarkers of liver fibrosis.

    Poynard T et al. · Adv Clin Chem · 2008 Match 69

    Liver biopsy, due to its limitations and risks, is an imperfect gold…

    ActiTest FibroTest SteatoTest Alcohol +5

  194. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 69

    FibroTest Metabolic

  195. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Match 69

    ### Background No blood test has been shown to be effective in the…

    LCR1 LCR2 Alcohol HBV +4

  196. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.

    Naveau S et al. · Clin Gastroenterol Hepatol · 2005 Match 69

    ### Background & Aims The aim of this study was to determine the diagnostic…

    FibroTest Alcohol

  197. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015 Match 69

    ### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…

    ActiTest FibroTest Alcohol HBV +3

  198. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial.

    Poynard T et al. · J Viral Hepat · 2002 Match 68

    A liver fibrosis index was recently prospectively validated in a cross-sectional…

    FibroTest HCV

  199. Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers.

    Chládek J et al. · J Eur Acad Dermatol Venereol · 2013 Match 68

    ### Background Low-dose oral methotrexate (MTX) is an effective immunosuppressive therapy for…

    FibroTest Other

  200. Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis.

    Haseltine EL et al. · J Viral Hepat · 2015 Match 68

    Patients infected with hepatitis C virus (HCV) have differing levels of liver…

    FibroTest HCV

  201. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.

    Poynard T et al. · Aliment Pharmacol Ther · 2021 Match 68

    ### Background One of the unmet needs in patients with type 2 diabetes…

    FibroTest NashTest-2 SteatoTest Metabolic

  202. Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.

    Sadler MD et al. · Can J Gastroenterol Hepatol · 2015 Match 68

    ### Background Liver disease is the third leading cause of mortality in patients…

    FibroTest Other

  203. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients.

    Crisan D et al. · Hepat Mon · 2012 Match 68

    ### Background The prediction of fibrosis is an essential part of the assessment…

    FibroTest HCV

  204. Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest - comparison with histopathological assessment.

    Pokorska-Śpiewak M et al. · Clin Exp Hepatol · 2017 Match 67

    ### Aim Of The Study Was to evaluate liver disease severity in children…

    ActiTest FibroTest HBV HCV

  205. FibroMAX: towards a new universal biomarker of liver disease?

    Morra R et al. · Expert Rev Mol Diagn · 2007 Match 67

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest AshTest FibroTest NashTest +7

  206. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

    López Tórrez SM et al. · Front Nutr · 2024 Match 67

    ### Introduction A prognostic model to predict liver severity in people with metabolic…

    FibroTest Metabolic

  207. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.

    Friedrich-Rust M et al. · BMC Gastroenterol · 2010 Match 67

    ### Background FibroTest (FT) is the most frequently used serum fibrosis marker and…

    FibroTest HBV HCV Other

  208. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.

    Poynard T et al. · J Hepatol · 2013 Match 67

    ### Background & Aims Real-time shear wave elastography (SWE) is a new two…

    FibroTest Alcohol HBV HCV +3

  209. Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.

    Maisonnasse P et al. · Gastro Hep Adv · 2022 Match 67

    ### Background And Aims Apolipoprotein A1 (A1) and haptoglobin (HP) serum levels are…

    FibroTest COVID

  210. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus.

    Varaut A et al. · Transplantation · 2005 Match 66

    ### Background An accurate diagnosis of hepatitis C virus (HCV)-related liver lesions…

    FibroTest HCV

  211. Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso.

    Bonnard P et al. · Am J Trop Med Hyg · 2010 Match 66

    Liver fibrosis (LF) must be assessed before talking treatment decisions in hepatitis…

    FibroTest HBV

  212. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

    Zelber-Sagi S et al. · World J Gastroenterol · 2013 Match 66

    ### Aim To compare noninvasive methods presently used for steatosis detection and quantification…

    SteatoTest Metabolic

  213. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies.

    Poynard T et al. · Antivir Ther · 2010 Match 66

    ### Background Liver biopsy and virological end points are standard references for assessing…

    ActiTest FibroTest HBV HCV +1

  214. Combination of fibrosis tests: sequential or synchronous?

    Boursier J et al. · Hepatology · 2009 Match 66

    FibroTest HCV

  215. Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.

    El-Shabrawi MH et al. · Eur J Gastroenterol Hepatol · 2010 Match 66

    ### Background Hepatitis C virus (HCV) is a major cause of chronic hepatitis…

    ActiTest FibroTest HCV

  216. Glycogenic hepatopathy.

    Khoury J et al. · Hepatobiliary Pancreat Dis Int · 2018 Match 65

    ### Background Glycogenic hepatopathy (GH) is a disorder associated with uncontrolled diabetes mellitus…

    FibroTest Metabolic

  217. Effective use of FibroTest to generate decision trees in hepatitis C.

    Lau-Corona D et al. · World J Gastroenterol · 2009 Match 65

    ### Aim To assess the usefulness of FibroTest to forecast scores by constructing…

    FibroTest HCV

  218. Silymarin in non alcoholic fatty liver disease.

    Cacciapuoti F et al. · World J Hepatol · 2013 Match 65

    …On the contrary, Steato test, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and…

    SteatoTest Metabolic

  219. Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society.

    Petroff D et al. · Dig Liver Dis · 2018 Match 65

    FibroTest Metabolic

  220. Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.

    Fernandez M et al. · Eur J Gastroenterol Hepatol · 2015 Match 65

    ### Objective Fibroscan (FS) is a reliable noninvasive method for the diagnosis of…

    FibroTest Alcohol

  221. Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration.

    Castera L et al. · HIV Med · 2014 Match 65

    ### Objectives Combining noninvasive tests increases diagnostic accuracy for staging liver fibrosis in…

    FibroTest HCV HIV

  222. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients.

    Maor Y et al. · Haemophilia · 2007 Match 65

    Non-invasive biomarkers have gained popularity for estimating fibrosis stage. In our…

    FibroTest HCV

  223. Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.

    Jullian-Desayes I et al. · Respirology · 2016 Match 64

    ### Background And Objective Obstructive sleep apnoea (OSA) could be an independent risk…

    NashTest SteatoTest Metabolic

  224. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.

    Myers RP et al. · Dig Dis Sci · 2003 Match 64

    As an alternative to liver biopsy, an index of five biochemical markers…

    FibroTest HCV

  225. Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis.

    Brener S · Ont Health Technol Assess Ser · 2015 Match 64

    ### Background Liver fibrosis is a sign of advanced liver disease and is…

    Elasto-FibroTest FibroTest Alcohol HBV +3

  226. Prognostic value of liver fibrosis biomarkers: a meta-analysis.

    Poynard T et al. · Gastroenterol Hepatol (N Y) · 2011 Match 64

    ### Aims And Methods Several serum biomarkers such as FibroTest, aspartate transaminase-platelet…

    FibroTest Alcohol HBV HCV +3

  227. Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B.

    Dezanet LNC et al. · Liver Int · 2021 Match 64

    ### Background & Aims Data on liver fibrosis evolution and its involvement in liver…

    FibroTest HBV HIV

  228. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?

    Poynard T et al. · Gastroenterology · 2005 Match 64

    ActiTest FibroTest Alcohol HBV +3

  229. Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography.

    Corradi F et al. · Dig Liver Dis · 2009 Match 63

    ### Background Progression of recurrent hepatitis C is accelerated in liver transplant recipients…

    FibroTest HCV

  230. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.

    Jacqueminet S et al. · Clin Gastroenterol Hepatol · 2008 Match 63

    ### Background & Aims Patients with diabetes are at risk for nonalcoholic fatty liver…

    FibroTest SteatoTest Metabolic

  231. Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.

    Morali G et al. · Isr Med Assoc J · 2007 Match 63

    ### Background The Fibrotest-Actitest is a six-parameter scoring system that allows…

    ActiTest FibroTest Alcohol HBV +1

  232. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.

    Poynard T et al. · Am J Gastroenterol · 2005 Match 63

    ### Objectives The noninvasive serum markers, FibroTest-ActiTest (FT-AT), are an alternative…

    ActiTest FibroTest HBV

  233. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study.

    Zarski JP et al. · J Hepatol · 2012 Match 63

    ### Background & Aims Blood tests and transient elastography (Fibroscan™) have been developed as…

    FibroTest HCV

  234. The Higher Prevalence of Non-Alcoholic versus Alcoholic Steatohepatitis in Alcoholics.

    Gruszewska E et al. · Clin Lab · 2015 Match 63

    …The MCV value and AST/ALT ratio were higher in alcoholic steatohepatitis…

    AshTest NashTest Alcohol

  235. Evaluation of liver stiffness measurement by fibroscan as compared to liver biopsy for assessment of hepatic fibrosis in children with chronic hepatitis C.

    Awad Mel-D et al. · J Egypt Soc Parasitol · 2013 Match 62

    …0001), necroinflammatory activity grades, AST, ALT, total serum bilirubin, prothrombin time and…

    ActiTest FibroTest HCV

  236. Comparison of FibroTest-ActiTest with histopathology in demonstrating fibrosis and necroinflammatory activity in chronic hepatitis B and C.

    Uyar C et al. · Indian J Pathol Microbiol · 2010 Match 62

    ### Aims FibroTest and ActiTest are noninvasive tests used in determining the level…

    ActiTest FibroTest HBV HCV

  237. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.

    Bedossa P et al. · Hepatology · 2012 Match 62

    …This score was closely correlated with both alanine aminotransferase (ALT) and aspartate…

    Metabolic

  238. Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.

    Sagrini E et al. · Eur J Gastroenterol Hepatol · 2013 Match 62

    ### Objectives Staging liver fibrosis in chronic viral hepatitis C (HCV) patients is…

    FibroTest HCV

  239. [The value of noninvasive serological markers in hepatitis B].

    García-Samaniego J et al. · Gastroenterol Hepatol · 2014 Match 62

    Bloodless methods (serological and imaging) for evaluating hepatic fibrosis constitute a good…

    FibroTest HBV

  240. Late presentation of chronic viral hepatitis for medical care: a consensus definition.

    Mauss S et al. · BMC Med · 2017 Match 62

    ### Introduction We present two consensus definitions of advanced and late stage liver…

    FibroTest HBV HCV

  241. Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.

    Dominguez S et al. · J Antimicrob Chemother · 2010 Match 61

    ### Objectives To compare plasma antiretroviral concentrations in HIV-HCV co-infected and…

    FibroTest HCV HIV

  242. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Match 61

    FibroTest Alcohol

  243. FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C.

    Morra R et al. · Hepatology · 2008 Match 61

    FibroTest Alcohol HBV HCV

  244. GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics.

    Vanderschaeghe D et al. · Mol Cell Proteomics · 2009 Match 61

    Liver fibrosis is currently assessed by liver biopsy, a costly and rather…

    FibroTest HCV

  245. Meta-analyses of FibroTest diagnostic value in chronic liver disease.

    Poynard T et al. · BMC Gastroenterol · 2007 Match 61

    ### Background FibroTest (FT) is a biomarker of liver fibrosis initially validated in…

    FibroTest Alcohol HBV HCV +1

  246. Guidelines for the screening, care and treatment of persons with hepatitis C infection Key publication

    Match 61

    FibroTest HCV

  247. The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.

    Grigorescu M et al. · J Gastrointestin Liver Dis · 2007 Match 60

    ### Aim To assess the diagnostic value of FibroTest to discriminate between insignificant…

    FibroTest HCV

  248. Stage of liver fibrosis in patients with congenital bleeding disorders and infected with hepatitis C virus.

    Kucharska M et al. · Pol Arch Intern Med · 2017 Match 60

    ### Introduction Hepatitis C virus (HCV) is the major cause of chronic liver…

    FibroTest HCV

  249. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication

    Shiha G et al. · Hepatol Int · 2009 Match 60

    Liver fibrosis is a common pathway leading to cirrhosis, which is the…

    FibroTest SteatoTest HBV HCV +1

  250. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?

    Poynard T et al. · Expert Rev Mol Diagn · 2005 Match 60

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest FibroTest Alcohol HBV +2

  251. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2012 Match 60

    ### Background Preliminary data suggest that performance of non-invasive markers for liver…

    FibroTest HCV

  252. Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.

    Viglino D et al. · Sci Rep · 2018 Match 60

    Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Fatty Liver Disease (NAFLD…

    FibroTest NashTest SteatoTest Metabolic

  253. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.

    Asselah T et al. · Liver Int · 2018 Match 59

    ### Background & Aims Patients with chronic hepatitis C virus infection and advanced fibrosis…

    FibroTest HCV

  254. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

    Castéra L et al. · Gastroenterology · 2005 Match 59

    ### Background And Aims Transient elastography (FibroScan; Echosens, Paris, France) is a novel…

    FibroTest HCV

  255. Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients.

    Wu FM et al. · J Heart Lung Transplant · 2017 Match 59

    ### Background Hepatic fibrosis is highly prevalent in individuals with Fontan circulation. FibroSure…

    FibroTest

  256. Applicability and variability of liver stiffness measurements according to probe position.

    Ingiliz P et al. · World J Gastroenterol · 2009 Match 59

    ### Aim To investigate the liver stiffness measurement (LSM) applicability and variability with…

    FibroTest Alcohol HBV HCV +3

  257. Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations.

    Munteanu M et al. · Clin Biochem · 2008 Match 59

    FibroTest Alcohol HBV HCV +1

  258. Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B.

    Park MS et al. · Liver Int · 2015 Match 59

    ### Background & Aims Liver stiffness (LS) measurement using transient elastography and the FibroTest…

    FibroTest HBV

  259. Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

    Bush AM et al. · Aliment Pharmacol Ther · 2018 Match 58

    FibroTest Metabolic

  260. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients.

    Bourliere M et al. · Aliment Pharmacol Ther · 2008 Match 58

    ### Background Non-invasive liver fibrosis scores such as Hepascore (HS) have been…

    FibroTest HCV

  261. Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.

    Calin R et al. · J Clin Virol · 2013 Match 58

    ### Background Due to common routes of transmission, HIV and HBV are frequently…

    FibroTest HBV HIV

  262. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.

    Preda CM et al. · Liver Int · 2018 Match 58

    ### Background Direct antiviral agents (DAA) showed very good results in terms of…

    FibroTest HCV

  263. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 58

    ### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…

    SteatoTest

  264. Personalized management of cirrhosis by non-invasive tests of liver fibrosis.

    Wong GL et al. · Clin Mol Hepatol · 2015 Match 58

    Owing to the high prevalence of various chronic liver diseases, cirrhosis is…

    FibroTest Alcohol HBV HCV +1

  265. Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis.

    Więcek S et al. · Mediators Inflamm · 2020 Match 58

    Changes in the liver and bile ducts observed in patients diagnosed with…

    ActiTest FibroTest Other

  266. Liver fibrosis in adults with Fontan palliation: Do common screening studies predict disease severity?

    Ofei SY et al. · Int J Cardiol · 2015 Match 57

    FibroTest Other

  267. Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C.

    Leroy V et al. · J Hepatol · 2014 Match 57

    ### Background & Aims Fibrosis blood tests have been validated in chronic hepatitis C…

    FibroTest HBV HCV

  268. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

    Younossi ZM et al. · Gastroenterology · 2021 Match 57

    ### Background & Aim Fibrosis is an independent predictor of death in nonalcoholic steatohepatitis…

    FibroTest Metabolic

  269. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

    Poynard T et al. · Lancet · 1997 Match 57

    ### Background Our aim was to assess the natural history of liver fibrosis…

    HCV

  270. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.

    Bourliere M et al. · J Viral Hepat · 2006 Match 57

    Noninvasive indexes have been developed to predict fibrosis staging. The aim of…

    FibroTest HCV

  271. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.

    Poynard T et al. · BMC Gastroenterol · 2011 Match 57

    ### Background FibroTest (FT) is a validated biomarker of fibrosis. To assess the…

    ActiTest FibroTest Alcohol HBV +4

  272. HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C.

    Costa JM et al. · Clin Res Hepatol Gastroenterol · 2011 Match 56

    ### Background And Aim Three gene polymorphisms, interferon-lambda-3 (IL28B), inosinetriphosphatase (ITPA…

    ActiTest FibroTest HCV-GenoFibroTest SteatoTest +1

  273. FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.

    Patel K et al. · World J Gastroenterol · 2011 Match 56

    ### Aim To compare histological endpoint assessment using noninvasive alternatives to biopsy during…

    FibroTest HCV

  274. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.

    Beckebaum S et al. · Transplantation · 2010 Match 56

    ### Background This prospective, monocentric study was designed to assess the efficacy of…

    FibroTest Alcohol HBV HCV +2

  275. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy.

    Schmid P et al. · PLoS One · 2015 Match 56

    ### Objectives To evaluate the diagnostic performance of seven non-invasive tests (NITs…

    FibroTest HCV HIV

  276. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.

    Vergniol J et al. · Gastroenterology · 2011 Match 56

    ### Background & Aims Liver stiffness can be measured noninvasively to assess liver fibrosis…

    FibroTest HCV HIV

  277. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy.

    Shaheen AA et al. · Am J Gastroenterol · 2007 Match 56

    ### Background The accurate diagnosis of hepatitis C virus (HCV)-related fibrosis is…

    FibroTest Alcohol HBV HCV

  278. FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.

    Poynard T et al. · J Hepatol · 2011 Match 55

    ### Background & Aims EPIC-3 is a prospective, international study that has demonstrated…

    FibroTest HCV

  279. The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy.

    Xu XY et al. · PLoS One · 2014 Match 55

    Noninvasive biomarkers have been developed to predict hepatitis B virus (HBV)-related…

    FibroTest HBV

  280. Noninvasive diagnosis in alcohol-related liver disease. Review

    Hadefi A et al. · Health Sci Rep · 2020 Match 55

    ### Background Alcohol-related liver disease (ALD) represents a major cause of death…

    FibroTest Alcohol

  281. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Match 55

    ### Background No blood test has been shown to be effective in the…

    FibroTest LCR1 LCR2 Alcohol +3

  282. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.

    Terrier B et al. · J Hepatol · 2011 Match 55

    ### Background & Aims Recent findings in hepatitis C virus (HCV)-monoinfected patients have…

    ActiTest FibroTest HCV HIV

  283. Current Possibilities to Assess the Degree of Liver Fibrosis in Patients with Haemophilia Infected with HCV--Review.

    Kucharska M et al. · Adv Clin Exp Med · 2015 Match 55

    Haemophilia is an entity, wherein the HCV infection rate is greater than…

    FibroTest HCV

  284. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy?

    Maor Y et al. · Haemophilia · 2006 Match 54

    Liver biopsy remains the gold standard for the evaluation of fibrosis despite…

    FibroTest HCV

  285. Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection.

    Shaheen AA et al. · HIV Clin Trials · 2008 Match 54

    ### Background Accurately staging hepatitis C virus (HCV)-related fibrosis is crucial for…

    FibroTest HCV HIV

  286. Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis.

    Vermehren J et al. · Liver Int · 2012 Match 54

    ### Background Acoustic radiation force impulse (ARFI) imaging is a new non-invasive…

    FibroTest Alcohol HBV HCV +3

  287. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.

    Friedrich-Rust M et al. · J Clin Gastroenterol · 2010 Match 54

    ### Background In recent years noninvasive methods have been evaluated for the assessment…

    FibroTest SteatoTest Other

  288. Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali.

    Traoré F et al. · BMC Infect Dis · 2015 Match 54

    ### Background Hepatitis B (HB) infection is common in Mali. However, there is…

    ActiTest FibroTest HBV

  289. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.

    Akuta N et al. · J Gastroenterol · 2018 Match 54

    ### Background In the UNITY-3 study, 96% sustained virologic response (SVR12) rate…

    FibroTest HCV

  290. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 53

    ### Background And Aim One of the unmet needs in subjects with metabolic…

    ActiTest FibroTest NashTest NashTest-2 +3

  291. [Results transferability on RXL, ARX, X-Pand, BN2 (Dade Behring) and modular DP (Roche Diagnostics) analysers: application to component assays of fibrotest and Actitest].

    Imbert-Bismut F et al. · Ann Biol Clin (Paris) · 2005 Match 53

    The follow up of patients with chronic liver diseases and the data…

    ActiTest FibroTest HBV HCV

  292. Relationship between the Fibrotest and portal hypertension in patients with liver disease.

    Thabut D et al. · Aliment Pharmacol Ther · 2007 Match 53

    ### Background The best technique to estimate portal hypertension (PHT) is to measure…

    FibroTest Alcohol HBV HCV +2

  293. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2018 Match 53

    ### Background Although the FibroTest has been validated as a biomarker to determine…

    FibroTest Alcohol HBV HCV +1

  294. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.

    Pais R et al. · Eur J Intern Med · 2015 Match 53

    ### Unlabelled The association of NAFLD with chronic hepatitis C (CHC) has been…

    FibroTest SteatoTest HBV HCV +1

  295. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study).

    Degos F et al. · J Hepatol · 2010 Match 53

    ### Background & Aims The diagnostic accuracy of non-invasive liver fibrosis tests that…

    FibroTest HBV HCV HIV

  296. Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C.

    Boursier J et al. · Aliment Pharmacol Ther · 2014 Match 52

    ### Background Recent longitudinal studies have emphasised the prognostic value of noninvasive tests…

    FibroTest HCV

  297. Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.

    Poynard T et al. · PLoS One · 2016 Match 52

    ### Background And Aims Real-time shear wave elastography (2D-SWE) is a…

    ActiTest FibroTest SteatoTest Alcohol +3

  298. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.

    Poynard T et al. · Comp Hepatol · 2004 Match 52

    SUMMARY: BACKGROUND: Recent studies strongly suggest that due to the limitations and…

    ActiTest FibroTest HCV

  299. Management of the patient with SVR. Review

    Terrault NA et al. · J Hepatol · 2016 Match 52

    In the current era of therapy with direct-acting antiviral (DAAs) drugs…

    FibroTest HCV

  300. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication

    Poynard T et al. · Gastroenterol Clin Biol · 2008 Match 52

    This review summarizes the methodological aspects of the interpretation of non-invasive…

    ActiTest FibroTest SteatoTest Alcohol +5

  301. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.

    Poynard T et al. · Gastro Hep Adv · 2022 Match 52

    ### Background And Aims The liver cancer risk test (LCR1-LCR2) is a…

    FibroTest LCR1 LCR2 Surveillance-FibroTest +1

  302. Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.

    Poynard T et al. · Hepatol Commun · 2023 Match 51

    ### Background And Aims Gilbert syndrome (GS) is genotypically predetermined by UGT1A1*28…

    FibroTest

  303. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2020 Match 51

    ### Objective There is a controversy about the performance of blood tests for…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  304. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.

    Salkic NN et al. · Am J Gastroenterol · 2014 Match 51

    ### Objectives Extent of liver fibrosis is one of the most important factors…

    FibroTest HBV

  305. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

    Deckmyn O et al. · Biomedicines · 2022 Match 51

    In patients with non-alcoholic fatty liver disease (NAFLD) with or without…

    FibroTest Metabolic

  306. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Match 51

    ### Background Excessive alcohol consumption may lead to the development of alcohol-related…

    FibroTest Alcohol

  307. Ministère des Affaires Sociales et de la Santé Key publication

    Match 51

    FibroTest HBV HCV

Showing the full result list. The page is server-rendered and not paginated.